Literature DB >> 8637229

Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia.

S C Raimondi1, C H Pui, M L Hancock, F G Behm, L Filatov, G K Rivera.   

Abstract

We studied the fully banded chromosomes of 182 children with hyperdiploid (51-67) acute lymphoblastic leukemia (ALL) to better delineate the heterogeneity of this disease subtype. Forty-six percent of the cases had numerical changes exclusively, while the remainder had structural as well as numerical changes. Chromosome 21 was added most often (97% of cases), followed by chromosomes 6 (86%), X (81%), 14 (80%), 4 (76%), 18 (68%), 17 (68%), 10 (56%), 8 (34%) and 5 (26%). Chromosomal translocations, including the t(1;19)(q23;p13) and t(9;22)(q34;q11), were detected in only 20% of the cases, as compared with 50% in ALL in general. The most common structural alterations were duplication of the 1q arm and isochromosome of 17q, present in 25 (14%) and nine (5%) cases, respectively. The presence of absence of structural abnormalities in these cases did not influence event-free survival, as assessed in 168 patients enrolled in three successive protocols for children with newly diagnosed ALL. By contrast, patients with 51-55 chromosomes per leukemic cell (n=105) appeared to fare worse than the 56-67 subgroup (n=63) (5-year probability of event-free survival = 72 +/- 5% (s.e.) vs 86 +/- 5%; P=0.04 by the stratified log-rank test). The poorer prognosis of the 51-55 subgroup was partly due to the higher frequency of isochromosome of 17q; 6/7 patients with the isochromosome in this group have had an adverse event. Other unfavorable features within the hyperdiploid (51-55) ALL subgroup include a low prevalence of trisomies of chromosomes 4 and 10 and a higher proportion of patients with leukocyte counts greater than 50 X 10(9)/l when compared to hyperdiploid (56-67). Thus, ALL defined by 51-55 chromosomes appears to be a clinicobiologic entity quite distinct from cases with higher modal numbers.

Entities:  

Mesh:

Year:  1996        PMID: 8637229

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

1.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia.

Authors:  J L Wiemels; R N Smith; G M Taylor; O B Eden; F E Alexander; M F Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Kajsa Paulsson; Erik Forestier; Henrik Lilljebjörn; Jesper Heldrup; Mikael Behrendtz; Bryan D Young; Bertil Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Joseph L Wiemels; Michelle Kang; Jeffrey S Chang; Lily Zheng; Carina Kouyoumji; Luoping Zhang; Martyn T Smith; Ghislaine Scelo; Catherine Metayer; Patricia Buffler; John K Wiencke
Journal:  Blood Cells Mol Dis       Date:  2010-08-05       Impact factor: 3.039

4.  Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.

Authors:  Maria E Gonzalez; Matthew L DuPrie; Heather Krueger; Sofia D Merajver; Alejandra C Ventura; Kathy A Toy; Celina G Kleer
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

Review 5.  Factors in improved survival from paediatric cancer.

Authors:  J W Taub
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

6.  FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.

Authors:  Patrick Chang; Michelle Kang; Anny Xiao; Jeffrey Chang; James Feusner; Patricia Buffler; Joseph Wiemels
Journal:  BMC Cancer       Date:  2010-09-27       Impact factor: 4.430

7.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

Authors:  Monique L Den Boer; Marjon van Slegtenhorst; Renée X De Menezes; Meyling H Cheok; Jessica G C A M Buijs-Gladdines; Susan T C J M Peters; Laura J C M Van Zutven; H Berna Beverloo; Peter J Van der Spek; Gaby Escherich; Martin A Horstmann; Gritta E Janka-Schaub; Willem A Kamps; William E Evans; Rob Pieters
Journal:  Lancet Oncol       Date:  2009-01-08       Impact factor: 41.316

Review 8.  Cytogenetics and molecular genetics of acute lymphoblastic leukemia.

Authors:  Krzysztof Mrózek; David P Harper; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

9.  Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.

Authors:  Deborah French; Wenjian Yang; Cheng Cheng; Susana C Raimondi; Charles G Mullighan; James R Downing; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2008-12-09       Impact factor: 22.113

10.  High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols.

Authors:  Kajsa Paulsson; Erik Forestier; Mette K Andersen; Kirsi Autio; Gisela Barbany; Georg Borgström; Lucia Cavelier; Irina Golovleva; Sverre Heim; Kristiina Heinonen; Randi Hovland; Johann H Johannsson; Eigil Kjeldsen; Ann Nordgren; Lars Palmqvist; Bertil Johansson
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.